Severe psychiatric adverse effects, defined as major depression, thoughts of suicide, or attempted or successful suicide occurred with 4.7 percent of patients given 20 mg of Acomplia ( rimonabant ) per day versus 3.8 percent of those given a placebo according to the STRADIVARIUS study that involved 839 patients at 112 centers in North America, Europe, and Australia.
“A single patient in the placebo group attempted suicide, and a single patient in the rimonabant [ Acomplia ] group successfully completed suicide,” the paper noted.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.